THERRES is an extremely ambitious and innovative project, focusing on the association of immunotherapy with molecular oriented drugs in gastric cancer, as a modern method of treatment. The project aims to implement a new classification system to distinguish between gastric cancer subtypes and to characterize regulatory molecules of immune function (immune checkpoints)
Institutul Clinic Fundeni si cei patru parteneri (UMF Iasi Gr. Th. Popa, UMF Craiova, Institutul de Biologie si Patologie Celulara Nicolae Simionescu, Universitatea Bucuresti), organizații publice de cercetare cu tradiție in domeniul sanatate si bioinformatica, isi propun sa dezvolte colaborarea trans-disciplinara clinica, academica, economica si sa creeze prin sinergie o agenda comuna de CDI. Prin corelarea si coordonarea activitatilor si resurselor, proiectul se concentrează asupra valorificării noii infrastructuri de cercetare a partenerilor.
The Fundeni Clinical Institute and the 4 project partners (UMF Iasi, UMF Craiova, Institute of Cellular Biology and Pathology N. Simionescu, Bucharest University), public research organizations with tradition in the domains of health and bioinformatics research, have joined a transdisciplinary clinical, academic and economic cooperation with a common research agenda. By coordinating the research activities and resources of the partners, the project capitalizes on the new research infrastructure of the partners, who will benefit from experiment “checks” and mobility funds. The common research agenda will focus on a systematic multi-omic study of a significant cohort of pancreatic cancer patients, recruited from the reference clinical centres of the project partners.
The general objective of the ONCORAD project is the development of the institutional capacity for research and development of the project partners, specifically in the field of radio-pharmaceutics and nuclear techniques in oncology, as well as their use in imagistic studies and molecular based personalized treatment. The coordinating institution, IFIN-HH, a reference centre in nuclear physics at a European level will increase, through this consortium, the interconnection of already existing research in the fields of radiobiology and radio- pharmaceutics, as well as in personalized medicine in oncology.
The main aim of this project is the development of a microarray platform using gold structures, to be used for the specific detection, through florescence and SPR, of HPV strains in pregnant women, and as such, offering information for the statistical evaluation of the involvement of HPV infection in premature births. This aim will help overcome the restraints involving the cost of purchasing commercial microarray supports, as well as represent a flexible solution for the personalized development of chips, as well as develop the capacity of the consortium for research in this field.
The scope of TRACeR project is to establish molecular subtypes of hepatocellular cacinoma (HCC) triggered by HBV and HCV infection or without viral infection, based on the trasncriptomic profiles obtained by analyzing patient tissue samples and cell lines and to further evaluate the mechanistic responses of the identified subclasses to available drugs or combination of drugs.
The main objective of the project is strengthening scientific cooperation between Fundeni Clinical Instituteand Sir Run Run Shaw Hospital of Zhejiang Universityvia a joint project proposal which, through the execution method, is of major scientific and practical importance and is aimed at developing research knowledge and activities, as well as at increasing mobility of researchers, sharing experience and accessing high-level research infrastructure, regarding the validation of prospective angiogenic and inflammatory biomarkers of liver cancer recurrence after surgery. Both partners have similar scientific goals in potential for carcinoma, similar research infrastructure and the potential to develop together more effective therapeutic strategies.
Through the implementation of this project, INSMC as project coordinator, as well as its five consortium partners with ample expertise in onco-gynecology, wishes to develop a new strategy for personalized treatment, by identifying new possible biomarkers of evolution and prognosis of cancer in women. We are envisaging the detection of new signaling pathways through the identification of new angiogenesis markers, as well as immunotherapy targets, with the aim to reduce/inhibit tumor progression.
The main objective of the project was to investigate the anti-oxidant, protective and other effects of High-Density Green Photons (HDGP) on biological systems and the possible optical manipulations at different molecular and cellular levels.
The major goal of the project “Hepatocellular carcinoma stratification based on noninvasive markers” (HEPMARK) in accordance with the EEA Research Programme objectives was to stimulate multidisciplinary research by creating and supporting a network for translational science that brings together scientists from Romania, Norway and France. HEPMARK proposed a concept of research that would identify, using miRNAs expression, a high-risk group of patients with liver cancer who may develop intrahepatic recurrence/distant metastasis. As there was an unmet need to improve the accuracy of hepatocellular carcinoma (HCC) score stratification by incorporation of new non-invasive molecular assays. Moreover, the possibilities to develop the new systems that predict the likelihood of recurrence after curative treatment, including miRNA and angiogenetic factors are needed. Thus, our hypothesis is that primary liver cancers release miRNAs within exosomes transported in the peripheral blood that facilitate the metastatic niche. We intend to use miRNA circulating and angiogenic panel for HCC patients’ stratification. More accurate preoperative selection criteria will allow better patient selection and better allocation of the HCC patients in case of curative treatment.